STAT+: Treasury proposes major restrictions to U.S. investment in Chinese biotech sector

The Treasury Department proposed restrictions under the Comprehensive Outbound Investment National Security Act, or COINS. The plan would add biotechnology to industries where U.S. investment could raise national-security concerns. It targets future investment rather than every business connection between American and Chinese companies.

The proposal would prohibit U.S. companies from entering financial transactions with Chinese biotechnology companies. It would also cover Chinese manufacturers of biotechnology-related equipment and tools. This means the restrictions would reach both companies developing biotech products and businesses supplying specialized biotech hardware or instruments.

The rule is proposed, not described as final in the article. Biotechnology would join semiconductors, artificial intelligence, and quantum technology among the fields subject to COINS restrictions. However, the proposal would still allow American drugmakers to buy rights to medicines invented in China, preserving that form of commercial access.

The proposed rule reaches two kinds of Chinese businesses. It would affect biotechnology companies themselves and manufacturers that make biotechnology-related equipment and tools. The article therefore describes a restriction broader than one aimed only at companies inventing medicines or developing biological products.

For example, a U.S. company could be blocked from a financial transaction with a Chinese biotech company. It could also be blocked from a financial transaction with a Chinese manufacturer supplying biotech equipment or tools. The research firm Veda identified these categories when describing the proposal’s scope.

The article does not list specific companies or products. It does make clear that both business groups would fall within the proposed restriction. Biotechnology has been added to the COINS framework alongside semiconductors, artificial intelligence, and quantum technology, but the rule would still preserve some access to Chinese medicines through rights purchases.

The Comprehensive Outbound Investment National Security Act, or COINS, is a U.S. law concerning investment leaving the country. Its purpose is to restrict U.S. investment in industries considered important to national security. The Treasury Department’s proposed rule would implement that law for biotechnology.

Before biotechnology was added, the article identifies semiconductors, artificial intelligence, and quantum technology as industries subject to COINS restrictions. The department proposed placing biotechnology alongside them. In practical terms, the law provides the framework for limiting certain financial relationships between U.S. companies and businesses in covered Chinese industries.

The article gives no further detail about COINS’s full legal structure or enforcement process. It does show how the law would work here: Treasury proposes a rule, and that rule would prohibit specified financial transactions with Chinese biotech companies and manufacturers. The proposal would still permit American drugmakers to buy medicine rights.

The article identifies four technology fields covered by COINS after biotechnology is added. The fields are biotechnology, semiconductors, artificial intelligence, and quantum technology. Biotechnology is the newly proposed addition to the list described in the article.

The count comes from combining biotechnology with the three fields the article names as already included. Treasury’s proposal would therefore expand the range of industries where U.S. investment may face national-security restrictions. The focus is on investment and financial transactions, not on banning every commercial interaction.

The article does not provide a longer official list of all COINS-covered industries. It specifically identifies these four fields in discussing biotechnology’s addition. It also distinguishes investment restrictions from medicine-rights purchases: American drugmakers could still buy rights to medicines invented in China under the proposed rule.

The proposed rule would prohibit U.S. companies from entering financial transactions with Chinese biotechnology companies. It would also prohibit transactions with Chinese manufacturers of biotechnology-related equipment and tools. That is the central restriction described by the research firm Veda.

The rule would not close every route to Chinese biomedical innovation. American drugmakers could still buy the rights to medicines invented in China. In a typical rights transaction, a company obtains permission to develop, make, or sell a medicine under an agreement, rather than buying an ownership stake in the inventor. The article specifically preserves this possibility.

The proposal therefore separates investment from intellectual-property access. It would restrict certain financial relationships with Chinese biotech businesses while allowing a route to license or acquire medicine rights. The article presents this as a proposed rule, so it does not establish that these restrictions are already in force.

The article places biotechnology among industries considered important to national security, but it does not explain the department’s detailed reasoning. More broadly, biotechnology can affect a country’s ability to develop medicines, maintain health security, and produce biological materials or tools. Those capabilities can matter during emergencies and strategic competition.

For example, dependence on overseas sources for essential biological equipment or medicines could create vulnerabilities if supplies were disrupted. Biotechnology research can also have uses beyond ordinary commerce, including applications connected to public health and biological security. These are general reasons governments may treat the sector as strategically important.

The proposal reflects that broader policy concern by adding biotechnology to COINS restrictions. It would limit specified U.S. financial transactions with Chinese biotech businesses and equipment manufacturers. At the same time, it would still allow American drugmakers to buy rights to medicines invented in China, showing that the proposal distinguishes national-security investment controls from every form of trade.

Biotechnology is the use of living organisms, cells, or biological processes to develop products and technologies. In health care, one major result is a medicine created through biological research. The article focuses on this sector because Treasury proposed restricting certain U.S. investment in Chinese biotechnology.

Buying medicine rights is different from investing directly in the company that invented the medicine. Under a licensing agreement, the rights holder permits another company to develop, manufacture, or sell the medicine, often in exchange for payments or royalties. The second company receives defined commercial rights, but it does not necessarily purchase ownership of the inventor or fund the company as an investor.

The article says American drugmakers could still buy rights to medicines invented in China. It does not explain the contract terms or define biotechnology. The descriptions of biotechnology and licensing here use established general knowledge to clarify the distinction between acquiring medicine rights and entering a restricted financial transaction.